市場調查報告書

全球關節痛注射市場:成長,趨勢,及預測

Joint Pain Injections Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921999
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球關節痛注射市場:成長,趨勢,及預測 Joint Pain Injections Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

本報告提供全球關節痛注射市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,注射類型·用途·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 全球關節炎的流行和全球老年人口的增加
    • 對膝關節疼痛注射的需求超出了外科手術範圍
  • 市場阻礙因素
    • 注射的高成本
    • 償付的問題
  • 波特的五力分析

第5章 市場區隔

  • 注射各類型
    • 類固醇關節注射
    • 玻尿酸注射
    • 多血小板血漿(PRP)注射
    • 胎盤組織來源的基質(PTM)注射
    • 其他
  • 各用途
    • 肩膀·肘
    • 膝·腳踝
    • 脊椎關節
    • 髖關節
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Anika Therapeutics, Inc.
    • Bioventus.
    • Ferring Pharmaceuticals Inc.
    • Sanofi
    • Pfizer Inc.
    • Eli Lilly and Company
    • Flexion Therapeutics, Inc.
    • Teva Pharmaceuticals
    • Zimmer Biomet

第7章 市場機會及今後趨勢

目錄
Product Code: 67449

Market Overview

The rise in the prevalence of arthritis and musculoskeletal disorders is driving the demand for joint pain injections usage, especially among the population aged 65 years or older as they are more prone to joint pains.

According to the Arthritis Research UK report named, "The State of Musculoskeletal Health 2018", it is estimated that 17.8 million people live with a musculoskeletal condition in the UK. Which is around 28.9% of the total population. As oral medications do not relieve joint pains and most of the patients are not interested in approaching surgeries joint pain injections act as the most desirable procedures. However, lack of awareness regarding these injections and the high cost of the products might hamper the growth of the market.

Scope of the Report

Joint Pain Injections are the products that can be injected directly into the knee joint or any joints in the body to help relieve knee pain and inflammation quickly. For patients who have inadequate responses or contraindications to systemic anti-inflammatory or analgesic drugs, Joint Pain Injections are preferred.

Key Market Trends

Steroid joint injections Segment Holds Significant Market Share

Asteroid joint pain injection is a minimally invasive procedure that can relieve the pain caused by the joint inflammation temporarily.

Steroid joint pain injection comprises both corticosteroid and an anesthetic numbing agent such as lidocaine or bupivacaine. The drugs are delivered to the painful joint, inside the joint capsule.

Steroid injections will reduce the inflammation and are effective when administered into the painful area directly. The benefits can last for several months.

Market players are extensively focusing on the development of novel products with many advantages and also launching products frequently. For instance, in October 2017, Flexion Therapeutics, Inc. received U.S. Food and Drug Administration approval for its Zilretta™ (triamcinolone acetonide short-acting corticosteroid) an intra-articular extended-release injectable suspension for osteoarthritis knee pain.

North America holds the largest market share in Global Joint Pain Injections Market

North America is expected to dominate the market due to the high prevalence of musculoskeletal disorders that causes joint pains. Increasing awareness of the Non-invasive orthopedic treatments, continuous innovation in the implant technologies, and advanced healthcare facilities. According to the Centers for Disease Control and Prevention (CDC), chronic pain caused by arthritis affects millions of people in the United States every year. About one in four adults with arthritis, 15 million people report experiencing severe joint pain related to arthritis. A high adoption rate of advanced technologies is also the factors driving the growth of the market in this region. Additionally, major market players are making huge investments in research activities, which will eventually drive the market in North America.

Competitive Landscape

The global joint pain injections market is a moderately fragmented market. Market players focus on continuous product development and offering joint pain injections at competitive prices especially in developing countries. Key developments in the market include: In February 2017, Zimmer Biomet received U.S.FDA approval for its Gel-One Hyaluronate a hyaluronic acid injection for 26 weeks in patients for the treatments knee osteoarthritis and In May 2018, Teva Pharmaceuticals USA, Inc. received U.S.FDA approval for SYNOJOYNT as a pain reliever in patients with osteoarthritis in the knee.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Arthritis and Increasing Geriatric Population Worldwide
    • 4.2.2 Increasing Demand for Knee Pain Injections Over Other surgical Procedures
  • 4.3 Market Restraints
    • 4.3.1 High Costs of the injections
    • 4.3.2 Reimbursement Issues
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Type of Injection
    • 5.1.1 Steroid Joint Injections
    • 5.1.2 Hyaluronic Acid Injections
    • 5.1.3 Platelet-rich Plasma (PRP) Injections
    • 5.1.4 Placental Tissue Matrix (PTM) Injections
    • 5.1.5 Others
  • 5.2 Applications
    • 5.2.1 Shoulder & Elbow
    • 5.2.2 Knee & Ankle
    • 5.2.3 Spinal Joints
    • 5.2.4 Hip Joint
    • 5.2.5 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Anika Therapeutics, Inc.
    • 6.1.2 Bioventus.
    • 6.1.3 Ferring Pharmaceuticals Inc.
    • 6.1.4 Sanofi
    • 6.1.5 Pfizer Inc.
    • 6.1.6 Eli Lilly and Company
    • 6.1.7 Flexion Therapeutics, Inc.
    • 6.1.8 Teva Pharmaceuticals
    • 6.1.9 Zimmer Biomet

7 MARKET OPPORTUNITIES AND FUTURE TRENDS